{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:34:34Z","timestamp":1768311274661,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,15]],"date-time":"2014-03-15T00:00:00Z","timestamp":1394841600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s40264-014-0145-z","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T02:43:53Z","timestamp":1395110633000},"page":"237-247","source":"Crossref","is-referenced-by-count":41,"title":["Dose-Specific Adverse Drug Reaction Identification in Electronic Patient Records: Temporal Data Mining in an Inpatient Psychiatric Population"],"prefix":"10.1007","volume":"37","author":[{"given":"Robert","family":"Eriksson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Werge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Juhl","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Brunak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,15]]},"reference":[{"key":"145_CR1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1345\/aph.1P627","volume":"45","author":"SV Tach\u00e9","year":"2011","unstructured":"Tach\u00e9 SV, S\u00f6nnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45:977\u201389.","journal-title":"Ann Pharmacother"},{"key":"145_CR2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00002018-200629020-00006","volume":"29","author":"CS Hooft Van der","year":"2006","unstructured":"Van der Hooft CS, Sturkenboom MCJM, van Grootheest K, Kingma HJ, Stricker BHC. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf. 2006;29:161\u20138.","journal-title":"Drug Saf"},{"key":"145_CR3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/pds.2118","volume":"20","author":"D Rottenkolber","year":"2011","unstructured":"Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salj\u00e9 K, Mueller S, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20:626\u201334.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"145_CR4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14656566.4.3.319","volume":"4","author":"S Gautier","year":"2003","unstructured":"Gautier S, Bachelet H, Bordet R, Caron J. The cost of adverse drug reactions. Expert Opin Pharmacother. 2003;4:319\u201326.","journal-title":"Expert Opin Pharmacother"},{"key":"145_CR5","volume-title":"The importance of pharmacovigilance","author":"World Health Organization","year":"2002","unstructured":"World Health Organization. The importance of pharmacovigilance. Geneva: World Health Organization; 2002."},{"key":"145_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1056\/NEJMp1206652","volume":"367","author":"J Avorn","year":"2012","unstructured":"Avorn J. Two centuries of assessing drug risks. N Engl J Med. 2012;367:193\u20137.","journal-title":"N Engl J Med"},{"key":"145_CR7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrd2378","volume":"6","author":"JA Kramer","year":"2007","unstructured":"Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov. 2007;6:636\u201349.","journal-title":"Nat Rev Drug Discov"},{"issue":"349","key":"145_CR8","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJMp038145","volume":"23","author":"WA Ray","year":"2003","unstructured":"Ray WA. Population-based studies of adverse drug effects. N Engl J Med. 2003;23(349):1592\u20134.","journal-title":"N Engl J Med"},{"key":"145_CR9","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2008.723","volume":"300","author":"JP Vandenbroucke","year":"2008","unstructured":"Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments how to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300:2417\u20139.","journal-title":"JAMA"},{"key":"145_CR10","doi-asserted-by":"crossref","unstructured":"Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: Wiley; 2007.","DOI":"10.1002\/9780470059210"},{"key":"145_CR11","doi-asserted-by":"crossref","unstructured":"Gibbons RD, Amatya AK, Brown CH, Hur K, Sue M, Bhaumik DK, et al. Post-approval drug safety surveillance. Annu Rev Public Health. 2010;31:419-37.","DOI":"10.1146\/annurev.publhealth.012809.103649"},{"key":"145_CR12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.2311","volume":"21","author":"MA Robb","year":"2012","unstructured":"Robb MA, Racoosin JA, Sherman RE, Gross TP, Ball R, Reichman ME, et al. The US Food and Drug Administration\u2019s Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf. 2012;21:9\u201311.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"145_CR13","doi-asserted-by":"crossref","DOI":"10.1002\/9781119959946","volume-title":"Pharmacoepidemiology","author":"BL Strom","year":"2012","unstructured":"Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. 5th ed. Chichester: Wiley; 2012.","edition":"5"},{"key":"145_CR14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"145_CR15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions a systematic review. Drug Saf. 2006;29:385\u201396.","journal-title":"Drug Saf"},{"key":"145_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.2053","volume":"20","author":"PM Coloma","year":"2011","unstructured":"Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR project. Pharmacoepidemiol Drug Saf. 2011;20:1\u201311.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"153","key":"145_CR17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-153-9-201011020-00010","volume":"2","author":"PE Stang","year":"2010","unstructured":"Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;2(153):600\u20136.","journal-title":"Ann Intern Med"},{"key":"145_CR18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrg3208","volume":"13","author":"PB Jensen","year":"2012","unstructured":"Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13:395\u2013405.","journal-title":"Nat Rev Genet"},{"issue":"20","key":"145_CR19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/amiajnl-2013-001708","volume":"1","author":"R Eriksson","year":"2013","unstructured":"Eriksson R, Jensen PB, Frankild S, Jensen LJ, Brunak S. Dictionary construction and identification of possible adverse drug events in Danish clinical narrative text. J Am Med Inf Assoc. 2013;1(20):947\u201353.","journal-title":"J Am Med Inf Assoc"},{"key":"145_CR20","doi-asserted-by":"crossref","first-page":"e1002141","DOI":"10.1371\/journal.pcbi.1002141","volume":"7","author":"FS Roque","year":"2011","unstructured":"Roque FS, Jensen PB, Schmock H, Dalgaard M, Andreatta M, Hansen T, et al. Using electronic patient records to discover disease correlations and stratify patient cohorts. PLoS Comput Biol. 2011;7:e1002141.","journal-title":"PLoS Comput Biol"},{"key":"145_CR21","volume-title":"Guidelines for ATC classification and DDD assignment, 2013","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2012","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2013. 15th ed. Norway: Oslo; 2012.","edition":"15"},{"key":"145_CR22","unstructured":"European Medicines Agency. Human medicines. 2012. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp . Accessed 27 Sep 2013"},{"key":"145_CR23","unstructured":"L\u00e6gemiddelstyrelsen. Produktresum\u00e9er\u2014human. 2012. http:\/\/www.produktresume.dk\/docushare\/dsweb\/View\/Collection-96 . Accessed 27 Sep 2013"},{"key":"145_CR24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40264-012-0002-x","volume":"36","author":"PM Coloma","year":"2013","unstructured":"Coloma PM, Avillach P, Salvo F, Schuemie MJ, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36:13\u201323.","journal-title":"Drug Saf"},{"key":"145_CR25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1517\/17425255.2010.509343","volume":"6","author":"R Garcia-Serna","year":"2010","unstructured":"Garcia-Serna R, Mestres J. Anticipating drug side effects by comparative pharmacology. Expert Opin Drug Metab Toxicol. 2010;6:1253\u201363.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"145_CR26","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","volume":"11","author":"P Perucca","year":"2012","unstructured":"Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792\u2013802.","journal-title":"Lancet Neurol"},{"key":"145_CR27","first-page":"553","volume-title":"Antipsychotic drugs. Rang and Dale\u2019s pharmacology","author":"PH Rang","year":"2011","unstructured":"Rang PH, Dale MM, Ritter JM, Flower RJ, Henderson G. Antipsychotic drugs. Rang and Dale\u2019s pharmacology. 7th ed. London: Elsevier; 2011. p. 553\u201363.","edition":"7"},{"key":"145_CR28","first-page":"487","volume-title":"Basic and clinical pharmacology","author":"H Meltzer","year":"2009","unstructured":"Meltzer H. Antipsychotic agents & lithium. In: Katzung BG, Masters S, Trevor AJ, editors. Basic and clinical pharmacology. 11th ed. New York: Lange Medical Books\/McGraw Hill; 2009. p. 487\u2013507.","edition":"11"},{"key":"145_CR29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002018-200022030-00004","volume":"22","author":"C Stanniland","year":"2000","unstructured":"Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf. 2000;22:195\u2013214.","journal-title":"Drug Saf"},{"key":"145_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/157488610789869256","volume":"5","author":"GA Keller","year":"2010","unstructured":"Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf. 2010;5:105\u201311.","journal-title":"Curr Drug Saf"},{"issue":"66","key":"145_CR31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2146\/ajhp070392","volume":"1","author":"J Stringer","year":"2009","unstructured":"Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Heal Syst Pharm. 2009;1(66):825\u201333.","journal-title":"Am J Heal Syst Pharm"},{"key":"145_CR32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/hup.465","volume":"18","author":"JF Pagel","year":"2003","unstructured":"Pagel JF, Helfter P. Drug induced nightmares: an etiology based review. Hum Psychopharmacol. 2003;18:59\u201367.","journal-title":"Hum Psychopharmacol"},{"issue":"93","key":"145_CR33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/clpt.2013.47","volume":"4","author":"P Lependu","year":"2013","unstructured":"Lependu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, Podchiyska T, et al. Pharmacovigilance using clinical notes. Clin Pharmacol Ther. 2013;4(93):547\u201355.","journal-title":"Clin Pharmacol Ther"},{"key":"145_CR34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.genhosppsych.2006.12.002","volume":"29","author":"JM Rothschild","year":"2007","unstructured":"Rothschild JM, Mann K, Keohane CA, Williams DH, Foskett C, Rosen SL, et al. Medication safety in a psychiatric hospital. Gen Hosp Psychiatry. 2007;29:156\u201362.","journal-title":"Gen Hosp Psychiatry"},{"issue":"69","key":"145_CR35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2146\/ajhp110026","volume":"15","author":"T Emmendorfer","year":"2012","unstructured":"Emmendorfer T, Glassman PA, Moore V, Leadholm TC, Good CB, Cunningham F. Monitoring adverse drug reactions across a nationwide health care system using information technology. Am J Health Syst Pharm. 2012;15(69):321\u20138.","journal-title":"Am J Health Syst Pharm"},{"key":"145_CR36","first-page":"376","volume-title":"Reducing suicide: a national imperative","author":"S Goldsmith","year":"2002","unstructured":"Goldsmith S, Pellmar T, Kleinman A, Bunney W. Reducing suicide: a national imperative. Washington, DC: National Academies Press; 2002. p. 376."},{"issue":"382","key":"145_CR37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"14","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;14(382):951\u201362.","journal-title":"Lancet"},{"key":"145_CR38","doi-asserted-by":"crossref","first-page":"125ra31","DOI":"10.1126\/scitranslmed.3003377","volume":"4","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4:125ra31.","journal-title":"Sci Transl Med"}],"updated-by":[{"DOI":"10.1007\/s40264-014-0158-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T00:00:00Z","timestamp":1397001600000}}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-014-0145-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0145-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0145-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T02:34:28Z","timestamp":1648607668000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-014-0145-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,15]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1007\/s40264-014-0145-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,15]]}}}